Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

NCT03307447 is registered in ClinicalTrials.gov with Narrows Institute for Biomedical Research as lead sponsor.

NCT NCT03307447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03307447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).
Lead sponsor
Narrows Institute for Biomedical Research
Phase
Phase 4
Overall status
Unknown status
Start date
December 19, 2017
Completion date
December 31, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris